Presenters shared their personal highlights of attending ASCO GI 2026. The 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium showcased not only transformative ...
New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...
Adding chemotherapy and bevacizumab to immunotherapy improves tumor control in a high-risk CRC subset, but this benefit comes ...
We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...
Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%), and at 24 months, the survival rate was nearly 5 times higher in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback